Debates continue regarding whether intravenous (IV) or intraperitoneal (IP)/IV therapies are superior for patients newly diagnosed with ovarian cancer. In this setting, the value of shared decision-making (SDM) had not been explored.
Debates continue regarding whether intravenous (IV) or intraperitoneal (IP)/IV therapies are superior for patients newly diagnosed with ovarian cancer. In this setting, the value of shared decision-making (SDM) had not been explored.